TEVAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (4 5月 2024 @ 00:02):

Stats
本日の出来高	1.68M
平均出来高	9.27M
時価総額	15.79B
EPS	$0 ( 2024-02-14 )
次の収益日	( $0.510 ) 2024-05-08
Last Dividend	$0.0850 ( 2017-11-27 )
Next Dividend	$0 ( N/A )
P/E	-28.17
ATR14	$0.0160 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Kalif Eliyahu Sharon	Buy	21 387	Ordinary Shares
2024-03-05	Kalif Eliyahu Sharon	Buy	52 320	Ordinary Shares
2024-03-06	Kalif Eliyahu Sharon	Sell	77 550	Ordinary Shares
2024-03-05	Kalif Eliyahu Sharon	Sell	21 387	Restricted Share Units
2024-03-05	Kalif Eliyahu Sharon	Sell	52 320	Restricted Share Units

INSIDER POWER
16.80
Last 98 transactions
Buy: 2 305 980 \| Sell: 1 612 593

ボリューム相関

長: 0.07 (neutral)

短: -0.42 (neutral)

Signal:(36.497) Neutral

Teva Pharmaceutical 相関

10 最も正の相関
UHS	0.848
NTZ	0.825
TGS	0.809
THD	0.809
VZ	0.805

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Teva Pharmaceutical 相関 - 通貨/商品

-0.41
( neutral )

-0.37
( neutral )

0.00
( neutral )

-0.43
( neutral )

0.09
( neutral )

Teva Pharmaceutical 財務諸表

Annual	2023
収益:	$15.85B
総利益:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2023
収益:	$15.85B
総利益:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2022
収益:	$14.93B
総利益:	$6.97B (46.72 %)
EPS:	$-2.12

FY	2021
収益:	$15.88B
総利益:	$7.60B (47.83 %)
EPS:	$0.380

Financial Reports:

No articles found.

Teva Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Teva Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 4.54 - low (50.68%) | Divividend Growth Potential Score: 0.404 - No dividend growth expected in the near future

Information

First Dividend	$0.00188	1987-02-23
Last Dividend	$0.0850	2017-11-27
Next Dividend	$0	N/A
Payout Date	2017-12-12
Next Payout Date	N/A
# dividends	125	--
Total Paid Out	$11.76	--
Avg. Dividend % Per Year	0.00%	--
Score	3.24	--
Div. Sustainability Score	4.54
Div.Growth Potential Score	0.404
Div. Directional Score	2.47	--

Next Divdend (Est)
(2024-06-10)

$0 Estimate 0.00 %

Dividend Stability

0.17 Bad

Dividend Score

3.24

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1987	$0.00802	1.94%
1988	$0.00964	2.40%
1989	$0.00807	1.81%
1990	$0.00919	1.23%
1991	$0.00938	1.28%
1992	$0.0105	0.75%
1993	$0.0161	0.56%
1994	$0.0175	0.46%
1995	$0.0271	0.90%
1996	$0.0250	0.43%
1997	$0.0310	0.50%
1998	$0.0411	0.68%
1999	$0.0276	0.52%
2000	$0.0413	0.47%
2001	$0.0648	0.39%
2002	$0.0906	0.59%
2003	$0.163	0.83%
2004	$0.201	0.69%
2005	$0.269	0.92%
2006	$0.306	0.69%
2007	$0.385	1.23%
2008	$0.503	1.07%
2009	$0.605	1.42%
2010	$0.748	1.29%
2011	$0.901	1.71%
2012	$1.034	2.40%
2013	$1.278	3.44%
2014	$1.366	3.39%
2015	$1.360	2.42%
2016	$1.360	2.08%
2017	$0.850	2.27%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0353	1.500	-0.706	-1.058	[0 - 0.5]
returnOnAssetsTTM	-0.0129	1.200	-0.429	-0.514	[0 - 0.3]
returnOnEquityTTM	-0.0762	1.500	-1.958	-2.94	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.019	0.800	9.90	7.92	[1 - 3]
quickRatioTTM	0.542	0.800	-1.520	-1.216	[0.8 - 2.5]
cashRatioTTM	0.263	1.500	9.65	10.00	[0.2 - 2]
debtRatioTTM	0.464	-1.500	2.27	-3.41	[0 - 0.6]
interestCoverageTTM	0.914	1.000	-0.773	-0.773	[3 - 30]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.751	2.00	9.62	10.00	[0 - 20]
debtEquityRatioTTM	2.68	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0593	1.000	-0.814	-0.814	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0679	1.000	-0.734	-0.734	[0.2 - 2]
assetTurnoverTTM	0.364	0.800	-0.904	-0.723	[0.5 - 2]
Total Score				4.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-28.24	1.000	-2.95	0	[1 - 100]
returnOnEquityTTM	-0.0762	2.50	-1.259	-2.94	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.751	2.00	9.75	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.452	1.500	-6.35	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				0.404

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

リアルタイムの更新： Teva Pharmaceutical [TEVA]

Upcoming Earnings Alert

Teva Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Commentary

Top 10 dividend Companies for NYSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)